Search

505 Result(s)
Sort by

BI_PharmAccess_launch_digital_healthcare_program

BI_PharmAccess_launch_digital_healthcare_program

Boehringer Ingelheim and PharmAccess launch a new mobile support program „Tiba Yako“ to empower patients to become more aware, access care and take charge of their disease management
Living with type 2 diabetes

Living with type 2 diabetes

People living with type 2 diabetes often suffer a degree of stigma. Learn from Jurjen de Lange what it takes to live a good life despite the disease.
Future of Diabetes

Future of Diabetes

This video highlights the evolution of type 2 diabetes management
Conversations Beyond Type 2 Diabetes

Conversations Beyond Type 2 Diabetes

Anne and Franc, who are living with T2D, explore what it means to live with their condition and its associated comorbidities.
empa-reg-outcome-recurrent-events

empa-reg-outcome-recurrent-events

EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease
CAROLINA-CARMELINA-Asia-analysis

CAROLINA-CARMELINA-Asia-analysis

CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes
CARMELINA-elderly-analysis

CARMELINA-elderly-analysis

CARMELINA® outcome trial subgroup analysis demonstrates long-term cardiovascular and renal safety data in older people with type 2 diabetes
Why cancer care is personal for us

Why cancer care is personal for us

At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Connect the Docs

Connect the Docs

Experts discuss interconnectivitiy of heart failure, diabetes, and kidney disease and the importance of early diagnosis.
real-world-benefit-shown-in-T2D-treatment

real-world-benefit-shown-in-T2D-treatment

Real-world evidence study shows type 2 diabetes treatment reduced risk of cardiovascular events and hospitalization for heart failure
It’s Your Heart. Protect It. The Podcast.

It’s Your Heart. Protect It. The Podcast.

In season 2, we hear from a range of experts to explore further how the interconnected systems call for collaboration and approach to care.
Phase 3 studies survodutide obesity and overweight

Phase 3 studies survodutide obesity and overweight

Phase 3 studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease